License and Disclaimer
The software which is provided is freeware for personal use only. It is not public domain software and may not be sold or used for commercial purposes. 
Permission to use and backup this software for any non-commercial purpose, without fee, and without a written agreement is hereby granted.
Permission to distribute this software for any non-commercial purpose, without fee, and without a written agreement is hereby granted, provided that a reference to the following website and the entire License and Disclaimer are provided with all distributed copies:

http://www.eortc.be/tools/imatinibtoxicity

The author has made every effort to ensure that the information provided by this software is accurate and conforms to the methods described in the publication.

However as indicated in the Discussion section of the publication, the models for occurrence of adverse events published in the paper and which are used in this software have only be validated on a limited data set. In addition, the occurrence of toxicity may depend on other factors than those taken into account here. Thus any decisions concerning patient care should not be based only on the use of this software, but should also take into account the patient's past history and other current patient characteristics.

As medical science is constantly changing and human error is always possible, the author and the EORTC do not warrant the software's accuracy nor are they responsible for any omissions, errors or outcomes resulting from the use of this software.

In no event shall either the author or the EORTC be liable to any party for any direct, indirect, special, incidental, or consequential damages, including lost profits, arising from the use of this software even if they have been advised of the possibility of such damage.

The author and the EORTC specifically disclaim any warranties, including but not limited to, the implied warranty of fitness for calculating the probabilities of occurrence of adverse events in patients with advanced Gastro-Intestinal Stromal Tumors treated with imatinib mesylate. The software provided hereunder is on an “as is” basis and neither the author nor the EORTC have any obligations to provide maintenance, support, updates, enhancements or modifications.